tesidolumab

Home
Ligands
tesidolumab

GtoPdb Ligand ID: 8711

Synonyms: LFG-316 | LFG316

Comment: Tesidolumab is a fully human monoclonal antibody targeting complement C5. Like eculizumab, this investigational monoclonal inhibits terminal complement activation.
Peptide sequence and secondary structural information for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence alignment analysis using the heavy and light variable domains of tesidolumab provide 100% matches to SEQ ID NOs 7 and 8 respectively from patent US8241628 [1]. These peptide sequences correspond to antibody (MOR0)8109 in said patent.

No information available.

No information available.

Summary of Clinical Use
Tesidolumab has reached Phase 2 clinical trial as a potential therapy for the ocular conditions, geographic atrophy, wet age-related macular degeneration and non-infectious uveitis.

Summary of Clinical Use

Tesidolumab has reached Phase 2 clinical trial as a potential therapy for the ocular conditions, geographic atrophy, wet age-related macular degeneration and non-infectious uveitis.

Mechanism Of Action and Pharmacodynamic Effects
Tesidolumab binds to and blocks the cleavage of the complement protein C5, thereby preventing the formation of C5a and membrane attack complex (C5b-9). It is hypothesised that this action will improve the complement dysregulation which underlies the pathological progression of age-related macular degeneration and associated geographic atrophy.

Mechanism Of Action and Pharmacodynamic Effects

Tesidolumab binds to and blocks the cleavage of the complement protein C5, thereby preventing the formation of C5a and membrane attack complex (C5b-9). It is hypothesised that this action will improve the complement dysregulation which underlies the pathological progression of age-related macular degeneration and associated geographic atrophy.